Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss. Tirzepatide is the first dual GLP-1/GIP receptor co-agonist which has been approved for treatment of type 2 diabetes mellitus (T2DM) based on the findings from the SURPASS program. The SURPASS trials assessed the safety and efficacy of tirzepatide in people with T2DM, from monotherapy through to insulin add-on in global populations, with another two trials dedicated to Japanese population. Over periods of treatment up to 104 weeks, once weekly tirzepatide 5 to 15 mg reduced glycosylated hemoglobin (1.87% to 3.02%), body weight (5.4 to 12.9 kg) and improved multiple cardiometabolic risk factors (including reduction in liver fat, new-onset macroalbuminuria, blood pressure, and lipids) across the T2DM spectrum. Tirzepatide provided better efficacy than placebo and other commonly used glucose-lowering medications such as semaglutide 1 mg, dulaglutide, insulin degludec, and glargine. All tirzepatide doses were well tolerated with similar side-effect profile to the GLP-1 receptor analogues. In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks. Overall, the SURPASS program and SURMOUNT-1 study suggest that tirzepatide is marking a new era in T2DM and/or obesity management through dual agonism of gut hormones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Selected ongoing clinical trials with tirzepatide (SURPASS program [green boxes], SURMOUNT program [red boxes], and other studies [blue boxes]). SURMOUNT-MMO, A Study of Tirzepatide on the Reduction on Morbidity and Mortality in Adults With Obesity; CV, cardiovascular; SURPASS-CVOT, A Study of Tirzepatide Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes; T2DM, type 2 diabetes mellitus; BMI, body mass index; SURPASSSWITCH, A Study of Tirzepatide in Adult Participants With Type 2 Diabetes Switching From Dulaglutide; HbA1c, glycosylated hemoglobin; SYNERGY-NASH, A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH); NASH, nonalcoholic steatohepatitis; SURMOUNT-OSA, Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide in Participants With Obstructive Sleep Apnea; SUMMIT, A Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; SURPASS-AP-Combo, A Study of Tirzepatide in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea; SURMOUNT-CN, A Study of Tirzepatide in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight.](https://figures.cochat.ai/paper-figures/229b2b689dae4661b9f41e8710a7d739/efficacy-and-safety-of-tirzepatide-in-type-2-diabetes-and-obesity-management-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tirzepatide is the first combination of entero-pancreatic hormones [dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) RA] that has been approved for T2D management based on the findings from the phase 3 SURPASS programme. The marked WL achieved with tirzepatide in the SURPASS trials led to the phase 3 SURMOUNT programme, assessing tirzepatide as treatment for obesity [16].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tirzepatide has been approved for T2D management - the mean HbA1c reduction in SURPASS programme ranged between 1.9 and 2.6% across the trials and 40–69% of participants achieved ≥10% WL with the higher doses (10 and 15 mg), despite that there was no additional support for lifestyle intervention [16, 43].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, pooled tirzepatide 10 mg and 15 mg was associated with consistent and significant improvements in glycaemic control, weight-related measures, and multiple cardiometabolic parameters compared with various comparator treatments in the SURPASS programme.11”
From Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies show that tirzepatide significantly reduced fasting blood glucose and HbA1c levels not only compared to placebo but also compared to degludec and glargine insulins or semaglutide.”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [95]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies in animals have also shown an anorexigenic effect of the GIP and in preclinical studies, the simultaneous activation of GLP-1 and GIP receptors leads to enhanced glucose-lowering effects and more WL compared to activating either receptor alone [21,38,39].”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Cited by
Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
“64 Among people with T2DM and/or obesity, a novel GLP1/glucose-dependent insulinotropic polypeptide receptor agonists (i.e., tirzepatide) 65 showed superior metabolic efficacy with improved serum aminotransferase level and liver fibrosis score, 66 although more evidence of the changes in liver…”
BackgroundWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“The marked WL achieved with tirzepatide in the SURPASS trials led to the phase 3 SURMOUNT programme, assessing tirzepatide as treat-ment for obesity [16].”
InfluentialSelf-citationSattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00027-0 · Cited by 131
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
“Phase III trials were carried out as part of the SURPASS programme to investigate its therapeutic effectiveness (glycaemic control and body weight reduction) and safety/tolerability for the treatment of patients with type 2 diabetes [90, 91].”
BackgroundChiappini, S., Vickers-Smith, R., Harris, D., Papanti Pelletier, G. D., Corkery, J. M., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Pharmaceuticals · doi:10.3390/ph16070994 · Cited by 78
Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214334 · Cited by 66
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“Overall, tirzepatide does not increase hypoglycemia risk unless combined with insulin or sulphony-lureas [18].”
InfluentialSelf-citationEffect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials
Kanbay, M., Copur, S., Siriopol, D., Yildiz, A. B., Gaipov, A., van Raalte, D. H., & Tuttle, K. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15272 · Cited by 56
“26 Tirzepatide induces substantial weight loss in most patients.”
BackgroundMelson, E., Miras, A. D., & Papamargaritis, D. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0144 · Cited by 46
Self-citationSztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“As part of the SURPASS program, phase III trials were conducted to evaluate the therapeutic efficacy (glycemic control and weight reduction), safety, and tolerability of tirzepatide in patients with T2DM [94,95].”
MethodCapuccio, S., Scilletta, S., Rocca, F. L., Miano, N., Marco, M. D., Bosco, G., Barbagallo, F. D. G., Scicali, R., Piro, S., & Pino, A. D. (2024) · Biomolecules · doi:10.3390/biom14060687 · Cited by 48
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“For example, the combination of GIP with GLP1-RAs has been shown to significantly improve MASH, reduce fibrosis, and decrease liver steatosis [345–347], while also having a synergistic effect on cardiometabolic risk factors [348–350].”
Yang, Y., Wang, Y., Zhou, Y., Deng, J., & Wu, L. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05066-1 · Cited by 35
Polypharmacology: new drugs in 2023–2024
Ryszkiewicz, P., Malinowska, B., & Schlicker, E. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00715-8 · Cited by 45
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
“This modification extends its half-life, making it suitable for a once-weekly subcutaneous injection formulation [85,86].”
BackgroundObesity medications: A narrative review of current and emerging agents
Qi, Q., Cox, A., McNeil, S. E., & Sumithran, P. (2024) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2024.100472 · Cited by 41
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“Tirzepatide (injectable, once weekly) is the first dual agonist (acting on GLP-1 and GIP receptors) approved for T2D and/or obesity management [21,35].”
BackgroundInfluentialSelf-citationGLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 34
“The efficacy of tirzepatide has generated interest in the development of further multi-receptor agonists that may provide enhanced therapeutic advantages while preserving good safety profiles (Sinha et al. 2023; Kusminski et al. 2024).”
Mahar, M. U., Mahmud, O., Ahmed, S., Qureshi, S. A., Kakar, W. G., & Fatima, S. S. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes24008 · Cited by 31
Tesfaye, H., Paik, J. M., Wexler, D. J., Carreno-Galeano, J. T., Yu, E. W.-Y., Freedman, A., Rizzo, J. F., & Patorno, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70200 · Cited by 24
Buonanno, S., Gaggiano, C., Terribili, R., Cantarini, L., Frediani, B., & Gentileschi, S. (2025) · Inflammation Research · doi:10.1007/s00011-025-02140-2 · Cited by 23
“All doses of tirzepatide were well tolerated, with a side-effect profile similar to that of GLP-1RAs [78].”
Perspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 22
“The general effects, particular the glycemic efficacy of tirzepatide were recently presented in several excellent review papers [1-6].”
BackgroundSallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Self-citationTian, Q., Song, Y., Deng, Y., & Lin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593134 · Cited by 26
“The dose-dependent effect observed in this meta-analysis further con fi rms previous reports on tirzepatide ’ s ef fi cacy (36, 37, 39).”
Arte, P. A., Tungare, K., Bhori, M., Jobby, R., & Aich, J. (2023) · Human Cell · doi:10.1007/s13577-023-01007-0 · Cited by 19
“Moreover, tirzepatide has demonstrated a favorable safety profile in clinical trials, with manageable side effects similar to other GLP-1RAs, which include common adverse events such as gastrointestinal symptoms of relatively lower magnitude such as nausea and vomiting [55].”
Zheng, W., Qi, Q., Li, J., He, C., & Fan, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01917-z · Cited by 19
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
“…2.5 mg can be made every minimum period of 4 weeks, reaching a maximum once-weekly dose of 15 mg. Based on the pharmacokinetics of tirzepatide, no dose adjustment is recommended based on age, gender, or body weight or in patients with hepatic or renal impairment (including those with ESRD) (160).”
InfluentialLiarakos, A. L., & Koliaki, C. C. (2023) · Biomedicines · doi:10.3390/biomedicines11071875 · Cited by 16
“Out of all these agents, tirzepatide (LY3298176, Mounjaro), a novel GIP/GLP-1 co-agonist (twincretin) that stimulates the GIP receptor more potently than the GLP-1 receptor [38], has emerged as a very promising drug in targeting metabolic dysfunction and has attracted a lot of interest in the literature [15,20,39].”
BackgroundReitz, J., Rosoff, D. B., Perlstein, T., Wagner, A., Jung, J., Wagner, J., Reiner, B. C., & Lohoff, F. W. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03199-3 · Cited by 18
Chen, L., Amraee, F., Sadegh‐Nejadi, S., Saberian, M., Ghahari, S. A., Miao, X., Lisco, G., & Afrisham, R. (2025) · European journal of medical research · doi:10.1186/s40001-025-03288-7 · Cited by 14
“T2DM is more common in obese than normal weight individuals [4].”
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
Panfili, E., Frontino, G., & Pallotta, M. T. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1171091 · Cited by 16
“Frontiers in Clinical Diabetes and Healthcare 03 medications, a systemic analysis reveals that GLP1-RAs and dual GLP-1/Gastric inhibitory polypeptide (GIP) agonists such as tirzepatide are most effective at causing weight loss in patients with type 2 diabetes (63).”
BackgroundGong, J., Gao, F., Jiang, K., Xie, Q., Zhao, X., & Lei, Z. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14340 · Cited by 20
“It acts mainly by activating the GLP-1 receptor thereby promoting insulin secretion and inhibiting glucagon release 9 .”
Tirzepatide a novel anti diabetic molecule unfold dual action
Sweta, Gupta, S., Bansal, S., Devi, S., Sharma, S., Laxmi, L., & Deepa (2024) · Discover Public Health · doi:10.1186/s12982-024-00200-2 · Cited by 14
“There was an observed average rise in pulse rate ranging from 0.7 to 8.3 beats per minute [54, 78].”
InfluentialRasouli, N., Wilding, J. P. H., Kwan, A. Y. M., Paik, J. S., Sharma, P., & Peleshok, J. C. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01711-0 · Cited by 16
“Among incretin-based therapies, GLP-1 receptor agonists (GLP-1 RAs) exert both insu-linotropic and glucagonostatic actions with additional cardiovascular benefits [4].”
Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review
Ramos, R. A. H., Hong, I., Ortiz, M., Secades, D., Krieger, S. D., & Stanziola, L. R. (2025) · Cureus · doi:10.7759/cureus.89020 · Cited by 17
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
“192,193 Initiated at 2.5 mg weekly and titrated to a maximum of 15 mg, tirzepatide has demonstrated dose-dependent reductions in HbA1c and body weight across the SURPASS trials.”
InfluentialAl-Sabah, S. K., Al‐Khairi, I., Jamal, M. H., Qaddoumi, M. G., Al-Ajmi, F. A., Kumar, J., ABUKHALAF, N. A., Cherian, P., Madhu, D., Arefanian, H., et al. (2024) · Medical Principles and Practice · doi:10.1159/000540534 · Cited by 14
“Tirzepatide, a dual GIP/GLP-1 receptor agonist has emerged as a potential therapeutic tool in the treatment of chronic metabolic diseases, such as T2D [14].”
BackgroundBridging the Gap: A Literature Review of Advancements in Obesity and Diabetes Mellitus Management
Pop, G. N., Manole, F., Buleu, F. N., Motofelea, A. C., Bircea, S., Popa, D. I., Motofelea, N., & Pîrvu, C. A. (2024) · Applied Sciences · doi:10.3390/app14156565 · Cited by 12
Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment
Napiórkowska-Baran, K., Treichel, P., Czarnowska, M., Drozd, M., Koperska, K., Węglarz, A., Schmidt, O., Darwish, S., Szymczak, B., & Bartuzi, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073769 · Cited by 12
“According to the SURPASS trials, which assessed the safety and efficacy of Tirzepatide in people with T2DM, it emerged that Tirzepatide improved multiple cardiometabolic risk factors, such as a reduction in liver fat, new-onset macroalbuminuria, blood pressure, and lipid profile [39,42].”
MethodXie, J., & Wang, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001320 · Cited by 12
“Additionally, a number of recently developed GLP-1 analogs, including tirzepatide, have been presented and have shown promising metabolic bene fi ts in a number of tests [45 – 49] .”
BackgroundMartins, A. C., de la Torre, B. G., & Alberício, F. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00039 · Cited by 11
GLP-1R mediates idebenone-reduced blood glucose in mice
Zhao, X., Zeng, Q., Yu, S., Zhu, X., Hu, B., Deng, L., Zhang, Y., & Liu, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117202 · Cited by 10
Wang, J., Chen, H., & Wang, X. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70392 · Cited by 9
“For example, human trials have documented negligible neurotoxic outcomes or neurological side effects at doses used clinically [18, 19, 22], while animal ‐ based research in noncancer settings revealed no notable harm to neural structures [49].”
Xu, P., He, Y., Wang, J., Sheng, Y., & Wang, J. (2025) · Foods · doi:10.3390/foods14173121 · Cited by 9
“It is important to note that this drug class can cause adverse reactions, particularly gastrointestinal issues such as nausea, vomiting, and diarrhea [5,6].”
Ghaleb, J., Khouzami, K. K., Nassif, N., Attieh, P., Ajlani, M. F. A., Sleiman, J. B., Khalouf, A., Harb, F., Azar, S. T., Kanaan, A., et al. (2025) · International Journal of Endocrinology · doi:10.1155/ije/2876156 · Cited by 11
“[14].”
InfluentialRecomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Alluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
“The safety and efficacy of TZP in T2D and obese patients has been extensively studied in various clinical trials such as SURPASS and SURMOUNT [21].”
Abdul‐Hafez, H. A., Awashra, A., Bdir, S., Saife, S., Salah, Q., Barbarawi, M., Swaileh, T., Emara, A., Elgendy, M. S., & Shubietah, A. R. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70152 · Cited by 9
Chen, H., Ding, Y., & Shan, Y. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468860 · Cited by 12
“Clinical studies have demonstrated that tirzepatide leads to greater reductions in glycated hemoglobin (HbA1c) and body weight than placebo or GLP-1 RAs, although it shares similar adverse drug events (ADEs), such as nausea and vomiting [9].”
Choi, H.-I., Jeong, H. C., Jeong, J., Lee, J., Kim, D. H., Ko, K., Chae, Y., & Lee, K. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124836 · Cited by 7
Mimura, H., Oura, T., Chin, R., Takeuchi, M., Fujihara, K., & Sone, H. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14395 · Cited by 8
“…in glycemic parameters is consistent with evidence suggesting that tirzepatide and other incretin-based therapies may provide better glycemic control in Asian patients compared with non-Asian patients 30,31 , possibly due to ethnic differences in beta-cell function and insulin sensitivity 31 .”
Desai, A., Khataniar, H., Tabaku, F., Hashash, J. G., Farraye, F. A., & Kochhar, G. S. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01835-y · Cited by 7
“TZP uniquely targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, yielding greater reductions in body weight and improvements in metabolic parameters than many predecessor agents [17, 18].”
Exploring the Effects of Tirzepatide on Obstructive Sleep Apnea: A Literature Review
Wen, J., Nadora, D., Truong, A., Bernstein, E., How-Volkman, C., Razick, D., Akhtar, M., Razick, A. A., & Frezza, E. (2025) · Cureus · doi:10.7759/cureus.80164 · Cited by 9
“Despite the promising findings, only two studies investigated tirzepatide for OSA [10,12].”
Shifting the Scales: Tirzepatide's Breakthrough in Obesity Management
Sallam, M., Snygg, J., Allam, D., & Kassem, R. (2024) · Cureus · doi:10.7759/cureus.60545 · Cited by 6
“In contrast to traditional therapies, tirzepatide specifically influences multiple metabolic pathways, enabling it to potentially impact body weight through various mechanisms [2].”
BackgroundMethodResultInfluentialEllberg, C. C., Schwartz, H. R., Witt, A., McCowen, K. C., Fuentes, A. L., & Malhotra, A. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-025-00384-1 · Cited by 6
“Tirzepatide, a dual agonist, has shown even greater efficacy in weight loss than GLP1RA alone [ 44, 45, 50].”
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
Botticelli, L., Bonaventura, E. M. D., Einaudi, G., Provensi, G., Costa, A., D'Addario, C., Cifani, C., & Bonaventura, M. V. M. D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70196 · Cited by 5
Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes
Patoulias, D., Popovic, D. S., Koufakis, T., Stavropoulos, K., & Doumas, M. N. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.12.022 · Cited by 5
Baran, K., Jankowska, M., Jańczyk, N., Mędrysa, K., Pokrzepa, J. J., Presak, M., Blecharz, G., Szwech, J., Winkowska, A., & Machalica, J. (2024) · Quality in Sport · doi:10.12775/qs.2024.30.56469 · Cited by 4
Oe, Y., Nomoto, H., Cho, K. Y., Omori, T., Nakamura, K., Takahashi, A., Suzuki, Y., Yoshikawa, J., Kato-Sato, A., Furukawa, S., et al. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251378216 · Cited by 4
“The SURPASS clinical trials reported the efficacy of tirzepatide worldwide, 14 and the SURPASS J-mono and J-combo trials were conducted in Japanese subjects.”
InfluentialKamrul-Hasan, A. B. M., Chatterjee, S., Ashraf, H., Nagendra, L., Dutta, D., & Pappachan, J. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.010 · Cited by 5
Banji, D., Alshahrani, S., Alfarhan, M., & Banji, O. J. F. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00050-2 · Cited by 4
“Tirzepatide helps increase feelings of fullness and suppress hunger signals, making it easier to eat less, while GIP receptor activation amplifies these effects by modulating fat metabolism and energy storage (Lopez-Mendez et al. 2023; Sinha et al. 2023).”
Seijas‐Amigo, J., Salgado‐Barreira, Á., Rodríguez‐Penas, D., Cardeso-Paredes, B., Ribeiro-Ferreiro, M., Rodríguez‐Mañero, M., & González-Juanatey, J. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02099-y · Cited by 4
Role of Microneedles for Improved Treatment of Obesity: Progress and Challenges
Chilamakuri, S. N., Manasa, N., Thalla, M., Ravichandiran, V., Lee, Y., Cho, S. M., Jung, H., & Natesan, S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01115 · Cited by 5
Tizerpatida: a nova promessa contra a obesidade
de Carvalho, G. M. L., & Barros, L. A. S. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-100 · Cited by 8
Tirzepatide: a dual-action solution for obstructive sleep apnea and obesity
Afridi, Z., Farhan, K., Fahad, F., Khan, M. W. Z., & Salomon, I. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002975 · Cited by 6
“Tirzepatide is a synthetic peptide based on GIP, which acts as a receptor agonist (RA) for both GIP and glucose-like peptide-1 (GLP-1) [ 3-5 ] .”
He, Y., Zeng, C., Zhang, Y., Wu, Q., Xiao-yu, Z., Yan, P., Xu, Y., Guo, M., & Teng, F. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70097 · Cited by 3
Kamrul-Hasan, A. B. M., Chatterjee, S., Nagendra, L., Dutta, D., & Pappachan, J. M. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf238 · Cited by 5
Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes
Shloush, M., Rodriguez, V., Guillen, V., & Baruqui, D. L. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2026-0028 · Cited by 5
“Tirzepatide is increasingly utilized in both patients with diabetes and patients without diabetes for weight control (1,2).”
Harbi, M. H., Ashour, A. M., Alorfi, N. M., Aldurdunji, M. M., Wali, S. M., & Alzahrani, Y. A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1764664 · Cited by 4
Dsouza, P. D., Chitralu, S. P. P., Khan, R., & Nyamagoud, S. B. (2025) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_386_24 · Cited by 3
Opalska, L., Muciek, A., Mocarska, M., Orłowska, A., Strakowska, K., Maryńczak, A., Mencel, J., & Nitschke, N. (2024) · Quality in Sport · doi:10.12775/qs.2024.35.56425 · Cited by 4
Natale, R., Morena, A., Capece, L. M., Donnarumma, S., Pagano, E., Pasanisi, F., & Santarpia, L. (2025) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2025_005823 · Cited by 2
Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers
Vetrano, E., Caturano, A., Nilo, D., Lorenzo, G. D., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Picco, S., Moretto, S. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18111703 · Cited by 3
“Tirzepatide is one of the most recent pharmacological options for the treatment of obesity and T2DM [61].”
Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison
Shil, K. K., Hira, A. D., Bakchi, S., Paul, S., Hossain, M., & Ghosh, D. K. (2025) · Cureus · doi:10.7759/cureus.98858 · Cited by 6
“On the other hand, tirzepatide, through its dual action on GLP-1 and GIP receptors, presents a novel therapeutic mechanism, potentially offering superior weight loss advantages over semaglutide when combined with lifestyle modifications [6].”
Hawas, Y., Abouzid, M., Gadelmawla, A. F., Ewis, D. K., Khatatbeh, A. E., Negida, Y., & Negida, A. (2026) · Brain and Behavior · doi:10.1002/brb3.71702 · Cited by 2
“…to be due to TZP established systemic cardiovascular and metabolic effects, blood-pressure reduction, lipid improvement, and better endothelial function (Sinha et al. 2023 ; Syed 2022 ), rather than to direct central neuroprotection, illustrating the direct-versus-indirect distinction drawn above.”
Tirzépatide : les leçons du programme clinique SURPASS
Bordier, L., Gourdy, P., & Guerci, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.07.001 · Cited by 2
Medikamentöse Adipositastherapie in Deutschland
Blüher, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01897-2 · Cited by 4
Zhang, J., Xu, H., Dong, Y., Feng, J., & Li, R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118024 · Cited by 2
Das, S., Ravi, H., Babu, A., Banerjee, M., Ramasubbu, K., Sivaraman, D., Rajeswari, V. D., Venkatraman, G., & Ramanathan, G. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.017 · Cited by 1
Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
Jaroń, A., Wiklińska, A., Jastrzębska, K., Witkowska, M., Skotnicka, J., Błaszczak, K., Turek, M., Wojciechowska, K., Borkowski, A., & Sawicki, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.53831 · Cited by 2
Tirzepatide – a new hope for type 2 diabetes mellitus and obesity management. A literature review.
Stawicka, I., Orzołek, I., Jarmołowicz, J., Boczar, A., & Dryja, P. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.71.55971 · Cited by 1
Pyeritz, R. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-812531-1.00001-4 · Cited by 1
Arvate, H. R. (2025) · International Journal of Nutrology · doi:10.54448/ijn25102 · Cited by 1
Iftikhar, P., Khatri, C. P., Nanduri, S. R. D., Ramzan, M. A., & Sakalabaktula, K. S. K. (2025) · Cureus · doi:10.7759/cureus.87188 · Cited by 3
“In Southeast Asian populations, particularly among Chinese individuals, these GI issues are prevalent but generally mild and self-limiting [21].”
Tirzepatide and Obesity: A Narrative Review
Singh, A., Ahmad, R., Chowdhury, K., Narwaria, M., & Haque, M. (2025) · Advances in Human Biology · doi:10.4103/aihb.aihb_244_25 · Cited by 1
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Xie, J., Yang, Y., Chen, W., (45927), L. W., Weng, S., Lyu, Q., & Cao, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00722-7 · Cited by 1
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“The SURMOUNT program (Table 2) provides evidence of dose-dependent weight loss in individuals with obesity, with or without T2DM, and improvements in cardiometabolic risk factors [134, 225–227].”
Galasso, M., Verde, L., Patrone, R., Ragozzino, G., Annunziata, G., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1855886 · Cited by 2
Molecular, genetic, and pharmacological advances in type 2 diabetes (2015–2025)
Romero, R. C. (2026) · BioMolecular Concepts · doi:10.1515/bmc-2025-0059 · Cited by 1
Paccola, G. P., de Oliveira, R. F., Mochetti, M. M., Razera, F. P. M., Vecchi, R., & Montanher, R. C. P. (2026) · Clinical Obesity · doi:10.1111/cob.70111 · Cited by 1
Bastos, R. A., Lopes, A. G. B., OLIVIERI, B., Fraguas, J. V. A., & de Oliveira, É. À. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i4.5133 · Cited by 2
Eficácia e segurança do tirzepatida: uma revisão integrativa de literatura, 2024
Valente, R. D. C., Pinheiro, K. D., dos Santos, E. D. C. C., de Sousa, A. Q. D., Assunção, R. D. S., dos Santos, C. C. L., PIMENTEL, K. D. F., dos Reis, R. M., Cavalcante, J. B., Roman, R. D. O., et al. (2024) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.17n.5-014 · Cited by 1
Medicatie voor obesitas: vooruitgang en uitdagingen
Muskiet, M. H. A., & Boon, M. R. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1569-4 · Cited by 1
Yousif, A. B., Mudarres, M. F., Yousef, M. F., Badawi, A., & Hassan, E. A. (2024) · Yemen Journal of Medicine · doi:10.18231/j.yjom.2024.005 · Cited by 2
“11,12 Notably, tirzepatide indicated superior efficacy in reducing glycated hemoglobin levels and promoting weight loss in comparison to semaglutide.”
Jeon, J. H., & Kang, D. W. (2025) · Tetrahedron Letters · doi:10.1016/j.tetlet.2025.155730 · Cited by 1
Tirzepatide: a dual approach to combat obesity and obstructive sleep apnea
Naseem, S., Afreen, S., Fareha, S., Pushpa, C., & Reja, M. H. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20252496 · Cited by 1
Diabetes mellitus: An overview
Sonia, T. A., & Sharma, C. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30272-5.00007-x · Cited by 1
Metadata
- Authors
- Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J.
- Affiliations
- University of Leicester (GB)
- Corresponding author
- Papamargaritis, Dimitris
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2023-02-08
- Volume
- 32
- Issue
- 1
- Pages
- 25-45
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC10088547
- OpenAlex
- W4319460325
- Cited by
- 138
- References
- 91
- Citations by year
- 2026: 36 · 2025: 52 · 2024: 35 · 2023: 15
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by-nc)
- Funders
- National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, type 2 diabetes, obesity, GIP/GLP-1 receptor agonist, SURPASS trials, HbA1c, weight loss, cardiometabolic risk factors, drug safety, semaglutide, dulaglutide, insulin degludec, glargine, Japanese population
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.